MitrAssist develops a minimally invasive "valve-in-valve" implant designed to sit on top of the patient's native mitral valve and enhance its function. The system is intended to preserve natural valve functionality, minimize impact on heart physiology, conform to varying anatomies, and deliver long-lasting results while shortening procedure and recovery times. The approach is positioned for patients who are unsuitable for open-heart surgery. The company has a patent pending. MitrAssist is a portfolio company of The Trendlines Group's Misgav Venture Accelerator and is based in Tel Aviv, Israel. Proceeds from the recent raise will be used to complete transapical chronic animal studies, the company's next milestone.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2013